HANOVER

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Retrieved on: 
Wednesday, February 21, 2024

HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that Chief Executive Officer George Ng will present a corporate update at the 2024 BIO CEO & Investor Conference being held on February 26 – 27, 2024 at the Marriott Marquis in New York City.

Key Points: 
  • HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that Chief Executive Officer George Ng will present a corporate update at the 2024 BIO CEO & Investor Conference being held on February 26 – 27, 2024 at the Marriott Marquis in New York City.

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Retrieved on: 
Wednesday, February 14, 2024

HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces that CEO George Ng will present a corporate update at The Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference being held February 20 – 23, 2024.

Key Points: 
  • HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces that CEO George Ng will present a corporate update at The Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference being held February 20 – 23, 2024.
  • Mr. Ng will be available for one-on-one meetings throughout the conference.
  • Investors can attend the conference and request a meeting with Mr. Ng by registering here: https://www.microcaprodeo.com/

Forbes Ranks The Hanover Among America's Best Employers

Retrieved on: 
Wednesday, February 14, 2024

WORCESTER, Mass., Feb. 14, 2024 /PRNewswire/ -- The Hanover Insurance Group, Inc. (NYSE: THG) today announced it has been named one of "America's Best Mid-Size Employers" for 2024 by Forbes magazine. This is the ninth consecutive year the company has received this recognition.

Key Points: 
  • WORCESTER, Mass., Feb. 14, 2024 /PRNewswire/ -- The Hanover Insurance Group, Inc. ( NYSE: THG) today announced it has been named one of "America's Best Mid-Size Employers" for 2024 by Forbes magazine.
  • America's Best Midsize Employers 2024 were selected based on an independent survey of over 170,000 U.S. employees from all industry sectors working for companies employing at least 1,000 people.
  • The Hanover offers a work environment that fosters collaboration and provides career development opportunities for employees to meet their full potential.
  • To find out more about employment opportunities at The Hanover, please visit www.hanover.com/careers .

The Hanover and its Employees Contribute $1.5 Million to United Way, Other Nonprofits

Retrieved on: 
Thursday, February 8, 2024

(NYSE: THG) and its employees have raised $1.5 million for United Way and other nonprofit organizations across the country.

Key Points: 
  • (NYSE: THG) and its employees have raised $1.5 million for United Way and other nonprofit organizations across the country.
  • For more than 70 years, The Hanover has held its annual employee campaign to support United Way agencies and nonprofits in their local communities.
  • "The Hanover and its employees have a history of supporting their community through their annual campaign.
  • "We continue to be inspired by the support of United Way by The Hanover and its employees.

The Hanover Insurance Group, Inc. to Present at the Bank of America Securities 2024 Financial Services Conference

Retrieved on: 
Wednesday, February 7, 2024

WORCESTER, Mass., Feb. 7, 2024 /PRNewswire/ -- The Hanover Insurance Group, Inc. (NYSE: THG) today announced John C. Roche, president and chief executive officer, and Jeffrey M. Farber, executive vice president and chief financial officer, are scheduled to participate in a fireside chat at the Bank of America Securities 2024 Financial Services Conference on Wednesday, February 21, 2024, from 10:30 a.m. to 11:10 a.m. Eastern Time.

Key Points: 
  • WORCESTER, Mass., Feb. 7, 2024 /PRNewswire/ -- The Hanover Insurance Group, Inc. (NYSE: THG) today announced John C. Roche, president and chief executive officer, and Jeffrey M. Farber, executive vice president and chief financial officer, are scheduled to participate in a fireside chat at the Bank of America Securities 2024 Financial Services Conference on Wednesday, February 21, 2024, from 10:30 a.m. to 11:10 a.m. Eastern Time.
  • Roche and Farber will also host several one-on-one and group meetings with investors on February 21.
  • The fireside chat will be broadcast live through the company's website at www.hanover.com .
  • A replay of the event will be available on The Hanover's website after the conclusion of the event.

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Retrieved on: 
Tuesday, February 6, 2024

Processa is a clinical stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and Processa’s Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but also increase the probability of FDA approval for its Next Generation Chemotherapy (NGC) drugs following an efficient path to approval. The Company’s approach to drug development, based on more than 30 years of drug development experience, uses its proven Regulatory Science Approach, including the determination of the Optimal Dosage Regimen using the principles of the FDA’s Project Optimus Oncology initiative. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of these FDA-approved drugs while maintaining the existing mechanisms of killing the cancer cells. The advantages of Processa’s NGCs are expected to include fewer patients experiencing side effects that lead to dose discontinuation, more significant cancer response, and a greater number of patients -- over 250,000 patients treated each year for each drug -- who will benefit from each NGC drug. Currently under development are three next generation chemotherapy oncology treatments: Next Generation Capecitabine (PCS6422 and capecitabine to treat breast, metastatic colorectal, gastrointestinal, pancreatic, and other cancers), Next Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers), and Next Generation Irinotecan (PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers).

Key Points: 
  • HANOVER, MD, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on the Nasdaq Market and that the matter is now closed.
  • To regain compliance with the Rule, the Company’s ordinary shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on February 2, 2024.

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Retrieved on: 
Thursday, February 1, 2024

The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, were $7.0 million (excluding any proceeds that may be received upon the exercise of the common warrants).

Key Points: 
  • The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, were $7.0 million (excluding any proceeds that may be received upon the exercise of the common warrants).
  • H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering.
  • 333-276308) relating to the offering was declared effective by the Securities and Exchange Commission (the "SEC") on January 26, 2024.
  • The offering was made only by means of a prospectus forming part of the effective registration statement relating to the offering.

Honeygain Introduces Its Rebrand Leading The Industry To User-centric Approach

Retrieved on: 
Wednesday, January 31, 2024

As Honeygain approaches its fifth birthday as the leading crowdsourced web intelligence app, a full rebrand introduces new design solutions, characters, and overall style.

Key Points: 
  • As Honeygain approaches its fifth birthday as the leading crowdsourced web intelligence app, a full rebrand introduces new design solutions, characters, and overall style.
  • Honeygain views the rebrand as a chance to give a face-lift to the app already used by millions of people worldwide and better connect to its audience.
  • This rebranding process is focused on improving the user experience and creating a memorable visual representation of what Honeygain is.
  • From the beginning, Honeygain took its brand identity seriously and this rebrand only emphasizes the brand values that make this app unique.

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Retrieved on: 
Friday, January 26, 2024

The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, are expected to be $7.0 million (excluding any proceeds that may be received upon the exercise of the common warrants).

Key Points: 
  • The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, are expected to be $7.0 million (excluding any proceeds that may be received upon the exercise of the common warrants).
  • The offering is expected to close on or about January 30, 2024, subject to the satisfaction of customary closing conditions.
  • 333-276308) relating to the offering was declared effective by the Securities and Exchange Commission (the "SEC") on January 26, 2024.
  • The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering.

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Retrieved on: 
Thursday, January 25, 2024

HANOVER, MD, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces the successful completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine (“NGC-Cap”). From the Phase 1b data, two dosage regimens have been selected for the Phase 2 trial. The Phase 2 trial will be in advanced or metastatic breast cancer given FDA’s agreement that the Phase 1b data can be used to support the design of the Phase 2 trial in breast cancer.

Key Points: 
  • From the Phase 1b data, two dosage regimens have been selected for the Phase 2 trial.
  • The Phase 2 trial will be in advanced or metastatic breast cancer given FDA’s agreement that the Phase 1b data can be used to support the design of the Phase 2 trial in breast cancer.
  • The NGC-Cap Phase 1b trial evaluated capecitabine doses from 75 mg once a day (QD) to 225 mg twice a day (BID).
  • Although the primary objective of the Phase 1b trial in patients with advanced gastrointestinal (GI) cancer was not to evaluate efficacy, the Phase 1b trial was designed to provide some preliminary data on efficacy.